menu

Alloimmune Thrombocytopenia in the Fetus and Newborn

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Alloimmune Thrombocytopenia in the Fetus and Newborn

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    This program is no longer available for credit.

    Program Chairman:
    Roberto Romero, MD, DMedSci
    Chief, Perinatology Research Branch
    Division of Maternal-Fetal Medicine and Obstetrics
    Division of Intramural Research
    NICHD/NIH/DHHS
    Editor-in-Chief for Obstetrics
    The American Journal of Obstetrics and Gynecology

    As the platelet equivalent of hemolytic disease of the fetus and newborn, fetal and neonatal alloimmune thrombocytopenia (FNAIT) is an uncommon yet complex and life-threatening bleeding disorder that results from incompatibility between mother and baby for platelet-specific antigens. Despite relatively normal platelet function, in the setting of severe thrombocytopenia, intracranial hemorrhage is a consequence. Drs. Shulman and Bussel discuss advances in management strategies and concrete steps you can take to lower the risk and stop the progression of this disorder in your patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Host:
    Lee P. Shulman, MD, FACOG, FACMG
    The Anna Ross Lapham Professor and Chief
    Division of Clinical Genetics
    Feinberg School of Medicine of Northwestern University
    Chicago, IL

    Consulting Fees: Agile, Aspira, Bayer, Biogix, Celula China, Daiichi Sankyo, Mayne, Organon, Shield
    Other: Astellas (DSMB Chair)

    Faculty:
    James B. Bussel, MD
    Professor Emeritus of Pediatrics
    Division of Hematology/Oncology
    Department of Pediatrics
    Weill Cornell Medicine
    New York, NY

    Receives Royalties: UpToDate
    Consulting Fees: argenx, Janssen, Rallybio, Rigel, Sobi, UCB

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Estelle Perera has nothing to disclose.
    • Jay Runyon has nothing to disclose.
    • Robert Schneider, MSW, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the pathophysiology underlying fetal/newborn alloimmune disorders, with a focus on fetal/neonatal thrombocytopenia
    • Identify current diagnostic and treatment regimens for fetal and neonatal thrombocytopenia
    • Identify current issues in diagnosis and discuss current and future treatment options
  • Target Audience

    This activity is designed to meet the educational needs of maternal-fetal medicine physicians, obstetrician-gynecologists, nurse practitioners, and physician assistants.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

     

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until November 23, 2023. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    This program is no longer available for credit.

    Program Chairman:
    Roberto Romero, MD, DMedSci
    Chief, Perinatology Research Branch
    Division of Maternal-Fetal Medicine and Obstetrics
    Division of Intramural Research
    NICHD/NIH/DHHS
    Editor-in-Chief for Obstetrics
    The American Journal of Obstetrics and Gynecology

    As the platelet equivalent of hemolytic disease of the fetus and newborn, fetal and neonatal alloimmune thrombocytopenia (FNAIT) is an uncommon yet complex and life-threatening bleeding disorder that results from incompatibility between mother and baby for platelet-specific antigens. Despite relatively normal platelet function, in the setting of severe thrombocytopenia, intracranial hemorrhage is a consequence. Drs. Shulman and Bussel discuss advances in management strategies and concrete steps you can take to lower the risk and stop the progression of this disorder in your patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Host:
    Lee P. Shulman, MD, FACOG, FACMG
    The Anna Ross Lapham Professor and Chief
    Division of Clinical Genetics
    Feinberg School of Medicine of Northwestern University
    Chicago, IL

    Consulting Fees: Agile, Aspira, Bayer, Biogix, Celula China, Daiichi Sankyo, Mayne, Organon, Shield
    Other: Astellas (DSMB Chair)

    Faculty:
    James B. Bussel, MD
    Professor Emeritus of Pediatrics
    Division of Hematology/Oncology
    Department of Pediatrics
    Weill Cornell Medicine
    New York, NY

    Receives Royalties: UpToDate
    Consulting Fees: argenx, Janssen, Rallybio, Rigel, Sobi, UCB

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Estelle Perera has nothing to disclose.
    • Jay Runyon has nothing to disclose.
    • Robert Schneider, MSW, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the pathophysiology underlying fetal/newborn alloimmune disorders, with a focus on fetal/neonatal thrombocytopenia
    • Identify current diagnostic and treatment regimens for fetal and neonatal thrombocytopenia
    • Identify current issues in diagnosis and discuss current and future treatment options
  • Target Audience

    This activity is designed to meet the educational needs of maternal-fetal medicine physicians, obstetrician-gynecologists, nurse practitioners, and physician assistants.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

     

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until November 23, 2023. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

Facebook Comments

Schedule29 Mar 2024